Next report date
Report period
Q1 2024
EPS estimate
−0.25USD
Revenue estimate
—
−0.86USD
−25.79 MUSD
30.15 M
About Cognition Therapeutics, Inc.
Sector
Industry
CEO
Lisa R. Ricciardi
Website
Headquarters
Purchase
Employees (FY)
28
Founded
2007
FIGI
BBG001J2P8S7
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CGTX is 1.93 USD — it has decreased by 3.02% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cognition Therapeutics, Inc. stocks are traded under the ticker CGTX.
Cognition Therapeutics, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
CGTX stock is 8.11% volatile and has beta coefficient of 1.16. Check out the list of the most volatile stocks — is Cognition Therapeutics, Inc. there?
CGTX earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.24 USD resulting in a 7.22% surprise. The estimated earnings for the next quarter are −0.32 USD per share. See more details about Cognition Therapeutics, Inc. earnings.
Yes, you can track Cognition Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
CGTX stock has risen by 1.05% compared to the previous week, the month change is a 3.21% rise, over the last year Cognition Therapeutics, Inc. has showed a 7.82% increase.
CGTX net income for the last quarter is −8.14 M USD, while the quarter before that showed −6.75 M USD of net income which accounts for −20.63% change. Track more Cognition Therapeutics, Inc. financial stats to get the full picture.
Today Cognition Therapeutics, Inc. has the market capitalization of 75.27 M, it has decreased by 1.59% over the last week.
No, CGTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CGTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cognition Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 28.00 employees. See our rating of the largest employees — is Cognition Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cognition Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cognition Therapeutics, Inc. stock shows the neutral signal. See more of Cognition Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Cognition Therapeutics, Inc. future price: according to them, CGTX price has a max estimate of 9.00 USD and a min estimate of 5.00 USD. Read a more detailed Cognition Therapeutics, Inc. forecast: see what analysts think of Cognition Therapeutics, Inc. and suggest that you do with its stocks.